Evidence map›Paper›PMID 28641468›Full record

ArticleLeukemia & lymphoma2018

Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.

Jose D Sandoval-Sus, Julio C Chavez, Samir Dalia, Syeda Mahrukh Hussnain Naqvi, Chetasi Talati, Lisa Nodzon, Mohamed A Kharfan-Dabaja, Javier Pinilla-Ibarz

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia & lymphoma, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Association of Cytogenetics Aberrations andGlobal medical genetics · 2024
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jose D Sandoval-Susa H. Lee Moffitt Cancer Center and Research Institute, University of South Florida , Tampa , FL , USA.
Julio C Chavezb Department of Malignant Hematology , H. Lee Moffitt Cancer Center and Research Institute , Tampa , FL , USA.
Samir Daliac Mercy Clinic Oncology and Hematology , Joplin , MO , USA.
Syeda Mahrukh Hussnain Naqvid Department of Biostatistics and Bioinformatics , H. Lee Moffitt Cancer Center and Research Institute , Tampa , FL , USA.
Chetasi Talatia H. Lee Moffitt Cancer Center and Research Institute, University of South Florida , Tampa , FL , USA.
Lisa Nodzonb Department of Malignant Hematology , H. Lee Moffitt Cancer Center and Research Institute , Tampa , FL , USA.
Mohamed A Kharfan-Dabajae Department of Blood and Marrow Transplantation , H. Lee Moffitt Cancer Center and Research Institute , Tampa , FL , USA.
Javier Pinilla-Ibarzb Department of Malignant Hematology , H. Lee Moffitt Cancer Center and Research Institute , Tampa , FL , USA.
Moffitt Cancer Center · USMercy Clinic Neurology · US

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5M
NCI NIH HHS P30 CA076292
6 · The paper itself

Abstract

Immunoglobulin heavy-chain variable region (IGHV) mutational status and karyotype abnormalities are important prognostic factors in chronic lymphocytic leukemia (CLL). The goal was to assess the impact of IGHV in CLL patients with isolated favorable genetic aberrations (del13q, trisomy 12, or negative fluorescence in situ hybridization [FISH]). We studied 273 CLL patients with both IGHV mutational status and cytogenetic information: 145 with isolated del13q 49 with sole trisomy 12 and 79 with negative FISH. After a median follow-up of 7.8 years, patients with del13q-unmutated IGHV had a shorter time to first treatment (TFT) (2.98 vs. 17.44 years; p < .001) and shorter overall survival (10.45 years vs. not reached; p = .0026). Patients with negative FISH-unmutated IGHV had shorter TFT (p = .02) (3.10 vs. 9.75 years, p = .053). IGHV status did not influence clinical outcomes in trisomy 12 CLL. In conclusion, IGHV mutational status shows prognostic impact in CLL patients with good prognosis genomic features.

Indexed as

GenomicsMutationAdultAgedAged, 80 and overBiomarkersChromosomes, Human, Pair 12FemaleHumansImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionIn Situ Hybridization, FluorescenceKaryotypeLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedBiomarkersImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionChronic lymphocytic leukemiagenomic abnormalitiesIGHVsurvival

Identifiers

PMID28641468
PMCPMC7771359
OpenAlexW2639428001

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.